Higher Antibody Concentrations in U.S. Health Care Workers Associated with Greater Reactogenicity Post-Vaccination.
SARS-CoV-2
antibody measurement
vaccine reactions
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
13 Apr 2022
13 Apr 2022
Historique:
received:
08
03
2022
revised:
04
04
2022
accepted:
08
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Multiple factors may be associated with immune responses to SARS-CoV-2 vaccines. Factors potentially related to magnitude and durability of response include age, time, and vaccine reactogenicity. This study analyzed SARS-CoV-2 IgG spike antibody responses following the second dose of vaccine in healthcare workers (HCWs). Data were collected from participants enrolled in a longitudinal SARS-CoV-2 serology study over a 12-month period. Participants completed a survey documenting symptoms post-vaccination. Serum specimens were tested for SARS-CoV-2 IgG antibodies using the Abbott Architect AdvisdeDx SARS-CoV-2 IgGII assay. Antibody levels were compared against time from second vaccine dose, and symptoms following vaccination. Altogether, 335 women (86.6%) and 52 men (13.4%) participated. Median age was 37 years (IQR 30-43). Overall median antibody level was 2150.80 [1246.12, 3556.98] AU/mL (IQR). Age was not associated with antibody concentration (p-value = 0.10). Higher antibody responses (2253 AU/mL vs. 1506 AU/mL; p = 0.008) were found in HCWs with one or more symptoms after the second dose of the vaccine (n = 311). Antibody responses persisted throughout the study period post-vaccination; statistically significant decreases in antibody responses were observed over time (p < 0.001). Higher antibody response was associated with reactogenicity post-vaccine. Age and sex were not associated with higher antibody responses.
Identifiants
pubmed: 35455350
pii: vaccines10040601
doi: 10.3390/vaccines10040601
pmc: PMC9031985
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Seattle Children's Hospital
ID : 410311830101
Références
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
J Infect. 2021 Sep;83(3):381-412
pubmed: 34161817
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32817144
Microbiol Spectr. 2021 Sep 3;9(1):e0024721
pubmed: 34190591
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Microorganisms. 2021 Mar 08;9(3):
pubmed: 33800489
JAMA. 2021 Dec 28;326(24):2524-2526
pubmed: 34724529
J Clin Virol. 2021 Mar;136:104765
pubmed: 33636554
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Infect. 2021 Aug;83(2):e4-e5
pubmed: 34214516
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
J Infect. 2021 Nov;83(5):559-564
pubmed: 34437927
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
N Engl J Med. 2021 Sep 30;385(14):1330-1332
pubmed: 34469645
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
J Clin Microbiol. 2021 Aug 18;59(9):e0123121
pubmed: 34166066
J Appl Lab Med. 2022 Jan 5;7(1):57-65
pubmed: 34342347
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Nov 18;385(21):2010-2012
pubmed: 34648703
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675
Hosp Pediatr. 2021 Mar;11(3):e48-e53
pubmed: 33361400
J Clin Microbiol. 2021 Aug 18;59(9):e0098921
pubmed: 34165323
Vaccines (Basel). 2021 Sep 01;9(9):
pubmed: 34579214
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
EClinicalMedicine. 2021 Jun;36:100928
pubmed: 34109307